| Document |
Document Title |
|
WO/2012/070059A1 |
Crystalline polymorphic forms of fingolimod hydrochloride, their XRPD patterns and preparation are provided. Processes for preparing crystalline polymorphic forms-α, β and μ substantially free from processes related impurities are als...
|
|
WO/2012/071102A2 |
A method of buffering a chemical or biological composition, comprising adding to the composition an effective buffering amount of at least one protonated or un-protonated amine-quaternary ammonium compound having a general formula(CI)d w...
|
|
WO/2012/061624A2 |
Methods and compositions for pest control, and more particularly for control of ants, e.g., of the subfamily Myrmicinae, using tyramides.
|
|
WO/2012/051246A1 |
The present invention provides a salt of Tapentadol, Tapentadol liydrobromide, and crystalline forms of Tapentadol hydrobromide.
|
|
WO/2012/050769A1 |
Described are novel monocationic polyhydroxyl compounds and their uses in personal care compositions.
|
|
WO/2012/046250A2 |
The present invention discloses polymorphic forms of O-desmethyl-venlafaxine succinate and processes for the preparation thereof.
|
|
WO/2012/041358A1 |
The invention relates to A process of making crystalline fingolimod hydrochloride of formula (Ia),comprising a step of contacting a solution of fingolimod hydrochloride in a solvent with an antisolvent, whereby crystalline fingolimod hyd...
|
|
WO/2012/044508A1 |
Provided is a process for making a tertiary aminoalcohol compound. The process comprises using an excess amount of a carbonyl compound in a condensation step between the carbonyl compound and a nitroalkane, and conducting a hydrogenation...
|
|
WO/2012/041405A1 |
The invention relates to a process of making fingolimod of formula (1), or an acid addition salt thereof comprising a step of reacting the compound of formula (11) and/or a compound of formula (14) or an acid addition salt thereof, in a ...
|
|
WO/2012/041707A1 |
The invention relates to a process of making fingolimod of formula (1), or an acid addition salt thereof comprising a step of reacting the compound of formula (11) and/or a compound of formula (14) or an acid addition salt thereof, in a ...
|
|
WO/2012/041359A1 |
The invention relates to a process of making fingolimod of formula (1), or an acid addition salt thereof comprising a step of reacting the compound of formula (11) and/or a compound of formula (14) or an acid addition salt thereof, in a ...
|
|
WO/2012/040133A2 |
Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal...
|
|
WO/2012/040151A2 |
Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal...
|
|
WO/2012/040138A2 |
Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal...
|
|
WO/2012/038974A1 |
Provided is a process for the preparing l-phenyl-3-dimethylaminopropane derivatives of formula I, (The formula should be inserted here) and its pharmaceutically acceptable salts thereof via novel intermediates.
|
|
WO/2012/037736A1 |
An ionic liquid solvent and gas purification method using the same are provided. The ionic liquid solvent consists of a main absorbent, regulator for the main absorbent, auxiliary absorbent, activator, antioxidant and water. It has a low...
|
|
WO/2012/031466A1 |
Disclosed are 2-(p-octylphenylethyl)-2-amino propanediol derivatives of formula (I) and uses thereof wherein, R1, R2, R3 is selected independently from H or acyl; R4 is selected from methylene, carbonyl, (II) or (III); R5 is trans-4-meth...
|
|
WO/2012/023546A1 |
The purpose of the present invention is to provide a process by which hydrogen or heavy hydrogens can be easily produced without using large-scale equipment and a process by which hydrogenation (protiation, deuteration or tritiation) can...
|
|
WO/2012/023147A1 |
Disclosed herein is an improved process for the preparation of 3-[(2R,3R)-1- (dimethylamino)-2-methylpentan-3-yl] phenol of Formula - I and its pharmaceutically acceptable salt which comprises the reaction of (S)-1-(dimethylamino)-2-meth...
|
|
WO/2012/013848A1 |
Difluorobenzyl ethanolamine derivatives with antimicrobial activity, belonging to the field of chemistry/medicine. Reference is made to a method for synthesizing fluorinated ethanolamine molecules, specifically difluorobenzyl ethanolamin...
|
|
WO/2012/010316A1 |
The invention relates to a salt or cocrystal of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)- phenol (component a) and at least one acid component (b1 ) or at least one acid component (b2), wherein the salt or cocrystal of component (a) a...
|
|
WO/2012/001571A1 |
The object of the present invention is a new process for the synthesis of tapentadol, both as free base and in hydrochloride form, which comprises the step of alkylation of the ketone (VII) to yield the compound (VIII), as reported in Di...
|
|
WO/2011/163155A2 |
Disclosed and claimed is a method of demulsifying an emulsion comprising water and oil. The method comprises adding an effective amount of a composition comprising at least one substantially fully quaternized ammonium adduct of polyephal...
|
|
WO/2011/157390A2 |
The present invention relates to a process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds.
|
|
WO/2011/155797A2 |
The present invention relates to hemioxalate of crystalline O-desmethylvenlafaxine which maximizes solubility and has physicochemical properties of a solid material which is pharmaceutically preferable due to its non-hygroscopicity, to a...
|
|
WO/2011/154152A1 |
The present application discloses a process for demethylating aromatic methyl ethers by reaction with 3 -mercaptopropionic acid or salts thereof. One preferred example is the demethylation of venlafaxine forming 0 - desmethylvenlafaxine.
|
|
WO/2011/150347A2 |
Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB recept...
|
|
WO/2011/147311A1 |
Compounds represented by formula (I), preparative method thereof and pharmaceutical compositions containing them and use thereof as immuno-regulation agents. The compounds can treat immunologic derangement, immunosuppression, hypoimmunit...
|
|
WO/2011/147576A1 |
The present invention relates to a process for the preparation of substituted 1-aminomethyl-2-phenyl-cyclohexane compounds.
|
|
WO/2011/143932A1 |
Provided are compounds shown by formula I, optical isomers, racemes, diastereoisomers, pharmaceutically acceptable salts or solvates thereof, wherein each substituent has the meaning as defined in the specification. Also provided are the...
|
|
WO/2011/141932A2 |
Disclosed herein is an improved and efficient process for preparation of fesoterodine and its pharmaceutically acceptable salt. Disclosed also herein is novel intermediate of formula (III). Also disclosed are metal salts of formula (XII)...
|
|
WO/2011/134724A2 |
The present invention describes a new method for preparing Ritodrinehydrochloride.The invention also concerns non-hygroscopic crystalline polymorphic Ritodrine hydrochloride Form (I).
|
|
WO/2011/131027A1 |
Preparation methods of L-phenylephrine hydrochloride by a major step of asymmetric hydrogenation and a series of special subsequent steps are provided, wherein, ruthenium-containing BINAP catalyst systems are used as the asymmetric hydro...
|
|
WO/2011/133893A2 |
The invention provides salts of sulfanegen and methods for their use.
|
|
WO/2011/125919A1 |
Disclosed are triarylamines represented by general formula (I). (In the formula, A1 to A3 each represents an optionally substituted phenylene group; X1 to X3 each independently represents a (substituted) phenyl group, and at least one of...
|
|
WO/2011/124927A1 |
According to the invention there is provided a compound of Formula (I) in which: A is a C2-8 alkylene group; R1, R2, R3, and R4 are independently selected from hydrogen, C1-4 alkyl, C2-4 dihydroxyalkyl in which the carbon atom attached t...
|
|
WO/2011/113926A1 |
The invention relates to a method for producing tin alkoxides. In particular, the invention relates to a method for directly synthesizing tin alkoxides of the general formula Sn(OR)n, where n = 2 or 4, from elemental tin by reacting the ...
|
|
WO/2011/115803A1 |
Provided is a process for making an aminoalcohol compound. The process comprises using an excess amount of aliphatic aldehyde in a condensation step between the aldehyde and a nitroalkane, and using an aldehyde scavenger in a reductive h...
|
|
WO/2011/110556A1 |
A process is described for the preparation of intermediates which can be used for preparation of agents for urinary incontinence therapy, specifically to 2-(3-(diisopropylamino)- 1-phenylpropyl)-4-(hydroxymethyl)phenol and its prodrugs.
|
|
WO/2011/110595A1 |
The present invention relates to salts present in crystalline form and/or to cocrystals of (+)- 3-[2-(dimethylamino)methyl-1-hydroxycyclohexyl]phenol or of (-)- 3-[2-(dimethylamino)methyl-1 -hydroxycyclohexyl]phenol containing cinnamic a...
|
|
WO/2011/107876A2 |
Provided herein is an improved and industrially advantageous optical resolution method for resolving (2R,3R)/(2S,3S)-l-dimethylamino-3-(3-methoxyphenyl)-2- methylpentan-3-ol, and use thereof for the preparation of tapentadol or a pharmac...
|
|
WO/2011/095576A1 |
A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 and Ar are as defined in description and in claims, can be used as a medicament.
|
|
WO/2011/097490A1 |
A method of preparing polyalkylated oligoalkylenepolyamines is provided. The method includes contacting oligoalkylenepolyamine with a reagent composition comprising (a) alkyl bromide and/or alkyl chloride; (b) a basic agent; and (c) iodi...
|
|
WO/2011/092719A2 |
The present invention provides a process for the preparation of 1-phenyl-3-dimethylaminopropane derivatives of formula I, and its pharmaceutically acceptable salts thereof from intermediate of formula II, wherein R1 can be selected from ...
|
|
WO/2011/086870A1 |
1,3,5-Tris(diarylamino)benzenes represented by general formula (I). In general formula (I), X1 to X6 are each independently an aryl group represented by general formula (II) [wherein R1 to R5 are each independently a hydrogen atom, C1-6 ...
|
|
WO/2011/085454A1 |
The present invention provides for novel benzene compounds and saccharide compounds and for the use of said compounds for binding, titration (quantification), removing, purifying or separating the glycoprotein gp120, gp120 comprising vir...
|
|
WO/2011/082994A1 |
The present invention relates to a method for reacting glycolaldehyde with an aminizing agent in the presence of hydrogen and a catalyst, the catalyst being activated by reducing a catalyst precursor or by reducing a passivated catalyst,...
|
|
WO/2011/082967A1 |
The invention relates to a method for producing ethanolamines by means of reacting glycol aldehyde with monoethanolamine and/or diethanolamine in the presence of a catalyst.
|
|
WO/2011/084273A1 |
Provided are aminoalcohol compounds for use as neutralizing agents for paints and coatings. The compounds are of the formula (I): or salt thereof, wherein R1, R2, R3, R4, R5, and n are as defined herein. Also provided are precursors of t...
|
|
WO/2011/084789A2 |
An integrated process is provided for efficiently preparing 2,4,5-triaminophenol, starting with nitration of 2,6-dihalobenzene; high purity salts thereof; and complexes of 2,4,5-triaminophenol aromatic diacids, which are precursors for m...
|
